recently checked on the official website of the Singapore Health Sciences Agency (HSA) that the "Lianhua Qingke Tablets" of Yiling Pharmaceutical has obtained the registration approval for "Chinese patent medicine" in Singapore.
The picture shows the Lianhuaqing cough tablets registration query results on the official website of the Singapore Health Sciences Bureau .
public information shows that Lianhua Qingke Tablets are another exclusive patented innovative Chinese medicine for the respiratory system approved for launch in May 2020 after Lianhua Qingwen . It promotes lung heat, relieves phlegm and relieves cough. It is a national medical insurance variety and is regarded by the market as Lianhua Qingwen's "sister medicine". In the treatment of symptoms such as cough and sputum, Lianhua Cough has the advantages of accurate efficacy, comprehensive effects and high safety.
On December 10, the National Administration of Traditional Chinese Medicine Administration of Traditional Chinese Medicine’s Expert Committee issued the “Guidelines for Traditional Chinese Medicine Intervention in People with New Coronavirus Infection at Home”, which mentioned that “If you have obvious symptoms, you should take Chinese patent medicines that have the effects of promoting lung and relieving cough, such as Lianhua Qingcough Tablets.”
In addition to the above "Guidelines", the drug has also been written into the novel coronavirus pneumonia traditional Chinese medicine diagnosis and treatment plan for six provinces (cities) in Beijing, Shandong, Hubei, Hebei, Sichuan and Fujian. Lianhua Qingke Tablets are also in the recently updated "Shandong Province Traditional Chinese Medicine Diagnosis and Treatment Plan for Influenza in Shandong Province (2022 Edition)" and "Fujian Province Traditional Chinese Medicine Prevention and Treatment of Influenza in 2022 (Trial)".
As a "Chinese patent medicine", Lianhua Qingke Tablets can be sold in Singapore's pharmacies, supermarkets, clinics, Chinese medicine hospitals and other channels.
Yiling Pharmaceutical announced that Lianhua Qingwen Capsule has also obtained the registration approval for the "Chinese Patent Medicine" approved and issued by the Singapore Health Sciences Bureau in May 2020.
The picture is a screenshot of the report of the official website of , Singapore Health Sciences Bureau , and was awarded , maturity level 4, .
It is understood that the Singapore Health Sciences Bureau became the first national regulatory agency to obtain the highest rating of World Health Organization (maturity level 4) in March this year. WHO has been conducting evaluations of medical regulatory agencies in various countries since 1997. The assessment standards cover the overall regulatory system, registration and marketing authorization, clinical trial supervision, etc., to ensure high standards, high quality and rigor of regulatory work.
This article comes from the financial world information
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-